Sesame

Sesame is a direct-to-patient telehealth marketplace that connects patients with independent, licensed healthcare providers for virtual and in-person appointments. Founded in 2018, it operates on a cash-pay model with transparent pricing set by individual providers, covering primary care, mental health, dermatology, weight loss, and more than 40 specialties. The platform does not accept insurance, positioning itself as an affordable alternative to insurance-based healthcare.

21/ 100
Early Warning
1No Decay→Stable

Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-10-26. Score revised 2026-10-26: 20 → 21.

Score History

MilestoneCriticalMajor
Direct-Pay Founding (2018–2020) · 10/100Direct-PayFoundingCOVID Telehealth Pivot (2020–2021) · 10/100COVID TelehealthPivotPlatform Expansion (2021–2023) · 17/100Platform ExpansionCostco-Era Growth (2023–2024) · 19/100Costco-E…GLP-1 Subscription Push (2024–present) · 21/100GLP-1 Subscription Push10075502502020202220242026-10Direct-Pay Founding (2018–2020) · 10/100COVID Telehealth Pivot (2020–2021) · 10/100Platform Expansion (2021–2023) · 17/100Costco-Era Growth (2023–2024) · 19/100GLP-1 Subscription Push (2024–present) · 21/1001010171921MilestonesFounded (2018)Series B ($27M, GV-led) (2022)Costco Partnership (2023)Events

Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.

Direct-Pay Founding
10/100
2018-10-18 – 2020-03-15

David Goldhill, Michael Botta and John Fontein founded the company as EasyCare Health in October 2018; it raised $3.4 million that year and $23.6 million in a 2019 offering. Sesame launched in early 2019 as a cash-pay marketplace for in-person visits at posted prices in Kansas City, Wichita and Oklahoma City. With a small user base, no memberships and nearly all business in person, there was little to extract from anyone.

COVID Telehealth Pivot
10/100
2020-03-15 – 2021-11-18

When the pandemic shut down in-person care, Sesame built a virtual visit service in five days and went from two local markets to 48 states by May 2020. It relaunched its brand in Houston and New York in September 2020, when the CEO described a 10% transaction fee, partnered with NantHealth in January 2021 and raised $24 million that April. Growth widened access while the model stayed simple pay-per-visit.

Platform Expansion
17/100+7
2021-11-18 – 2023-09-25

Sesame Plus, launched in November 2021 at $7 a month and reported at $10.99 by June 2022, brought recurring billing to a pay-per-visit marketplace, alongside SesameRx $5 generics, Sesame for Employers and the $27 million GV-led Series B that put a GV partner on the board. A 2022 academic study found trackers on Sesame's service sending appointment and lab details to Google, Facebook and Amplitude. Rival MDSave sued over alleged scraping and false advertising, a case dismissed with prejudice in 2023.

Costco-Era Growth
19/100+2
2023-09-25 – 2024-08-21

The Costco partnership offered Costco's 70-million-plus members $29 virtual primary care, $79 therapy and $72 checkups, and in April 2024 Sesame added a $179 Costco weight-loss program. Prices stayed posted and low, but growing scale brought more complaints about provider no-shows and membership billing.

GLP-1 Subscription Push
21/100+2
2024-08-21 – present

Success by Sesame made weight loss a monthly program, first with compounded semaglutide at $249 and then with branded Zepbound (March 2025) and the Wegovy pill (January 2026) after the FDA ended the semaglutide shortage. Chief Medical Officer Marty Makary left to run the FDA, and recurring plans spread to prescriptions (Everyday Rx) and fertility care (March 2026). Complaints about unwanted subscription charges and email-or-phone-only membership cancellation are the main drag on an otherwise transparent, well-rated marketplace.

Alternatives

Mark Cuban's transparent-pricing pharmacy with cost-plus-15% markup and $5 dispensing fee. No telehealth consultations, so you'd need a separate provider for prescriptions, but dramatically lower medication costs with full pricing transparency.

GoodRx46/100

Prescription discount platform whose free coupons lower cash prices at most major pharmacies, and which has offered low-cost cash-pay online visits through GoodRx Care. Easy switch -- just book a visit. Better for users who mainly want medication savings at their local pharmacy.

In the News

Dimensional Breakdown

Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.

User Value Erosion
Sesame remains well rated: 4.5 stars on Trustpilot, 88% of 100 users surveyed by HelpGuide satisfied, and more than one million patients served by June 2026 by the company's count. Its range keeps widening, from $29 Costco virtual primary care to fertility care (March 2026) and LillyDirect access (June 2026). Erosion shows in recurring complaints about provider no-shows, short prescription durations, pharmacies questioning Sesame prescriptions and a messaging window that warns providers may not respond within days of a visit, while the advertised starting visit price has risen from $25 in 2021 to $34.
How It Got Here
Sesame launched in 2019 as a small in-person marketplace in Kansas City, Wichita and Oklahoma City. The COVID-19 pivot in March 2020 took virtual care to 48 states within months, widening access for uninsured and high-deductible patients. The SesameRx pharmacy added $5 generics in August 2021, a state-paid California COVID-19 telehealth equity program followed in October 2022, and the Costco partnership in September 2023 brought $29 virtual primary care to Costco members. Expansion continued with weight-loss programs from 2024, a fertility program with Costco and IVI RMA in March 2026, and LillyDirect access in June 2026, when Sesame said it had served more than one million patients. Ratings stay high (4.5 on Trustpilot; 88% satisfied in a HelpGuide survey of 100 users), but recurring complaints on BBB, ConsumerAffairs and Reddit describe provider no-shows, short prescription durations that force repeat visits, pharmacies questioning Sesame prescriptions, and a messaging window that warns providers may not respond within days of an appointment. The advertised starting visit price has risen from $25 in 2021 to $34. The pattern is marketplace quality strain that grows with scale, not deliberate degradation.
Business Customer Exploitation
Shareholder Extraction
Lock-in & Switching Costs
Twiddling & Algorithmic Opacity
Dark Patterns
Advertising & Monetization Pressure
Competitive Conduct
Labor & Governance
Regulatory & Legal Posture

Dimension History

2018Direct-Pay Founding2020COVID Telehealth Pivot2021Platform Expansion2023Costco-Era Growth2024GLP-1 Subscription PushUser Value11123Biz Exploit11222Shareholder11222Lock-in11111Algorithms11222Dark Patterns11234Advertising11222Competition11111Labor/Gov11222Regulatory11222
Timeline (37 events)
major2018-10-18

Sesame founded as EasyCare Health in New York

David Goldhill, Michael Botta PhD, and John Fontein co-founded the company in Brooklyn as EasyCare Health, LLC, later renamed Sesame, Inc. Goldhill drew on his 2009 Atlantic article 'How American Health Care Killed My Father' and his book 'Catastrophic Care' to build a direct-pay healthcare marketplace bypassing insurance intermediaries. The company's first Form D, filed in November 2018 and signed by Goldhill as CEO, reported $3.4 million sold of a $3.95 million offering, with the first sale on October 26, 2018.

major2019-01-01

Sesame launches in-person marketplace in Kansas City and Oklahoma City

Sesame launched its direct-pay healthcare marketplace in early 2019, connecting patients with local providers for in-person visits at transparent, cash-pay prices; Google Cloud's case study names Kansas City, Wichita and Oklahoma City as the launch markets. By early 2020 it was operating in two small markets, Kansas City and Oklahoma City, and nearly 100% of its business came through in-person appointments. The platform targeted uninsured Americans and those with high-deductible plans.

minor2019-10-09

Sesame's 2019 Form D reports $23.6 million sold to 42 investors

Sesame's Form D, signed October 9, 2019, reported $23,648,688 sold to 42 investors in an exempt offering whose first sale was on September 25, 2019. Coming a year after the $3.4 million 2018 offering, it funded the company before its 2021 and 2022 announced rounds.

critical2020-03-15

Sesame builds virtual care platform in five days during COVID

As the COVID-19 pandemic shut down in-person care, Sesame's team built a virtual appointment system from wireframe to live service in five days. The pivot leveraged Google Kubernetes Engine, and Sesame went from two small local markets to a nationwide service in a few weeks (Google Cloud's case study says Cloud SQL helped it scale from two to 35 states in two weeks). By May 2020 it operated in 48 states, with 86% of bookings coming through virtual appointments.

major2020-09-09

Sesame expands to Houston and New York City with new brand

Sesame launched a new brand and expanded into Houston and New York City, presenting itself as a direct-to-patient marketplace with upfront prices for patients paying cash. About 100 vetted Houston providers were listed at launch, with appointment times and prices posted online. By then its telehealth service, launched in spring 2020, already reached 48 states.

minor2020-09-09

Sesame CEO describes a 10% transaction fee on bookings

In a September 2020 interview, CEO David Goldhill said Sesame made its money by charging a 10 percent transaction fee, like other marketplaces that match supply and demand in real time. Patients prepaid a posted price, which Goldhill said was the only price they would pay for the service.

minor2021-01-25

Sesame partners with NantHealth for provider network expansion

NantHealth and Sesame announced a collaboration giving providers registered on NantHealth's NaviNet payer-provider platform access to Sesame's direct-pay marketplace. The program was pitched as increasing practice revenue up to 25% per patient visit by reducing administrative costs.

major2021-04-27

Sesame raises $24M to expand nationwide telehealth

Sesame raised $24 million from new investors Giant Ventures, Industry Ventures, and Coefficient Capital, with existing backers General Catalyst, Entree Capital, and Atreides Management contributing. The round brought total capital raised to nearly $50 million. Funds were earmarked for expanding nationwide telehealth offerings and growing the provider network.

major2021-08-31

SesameRx digital pharmacy launches with $5 generics

Sesame unveiled SesameRx, an online pharmacy offering around 200 FDA-approved generic medications at $5 each with free nationwide delivery and no insurance required. The pharmacy was powered by Truepill's URAC-accredited pharmacy footprint. Patients could receive prescriptions during Sesame consultations, covering conditions from allergies to diabetes to ADHD.

major2021-11-18

Sesame Plus membership program launches

Sesame introduced its first-ever membership program: a free Sesame Basic tier and Sesame Plus at $7 per month, which added an extra 25% off primary care visits and other discounts; Sesame estimated Plus members would save $200+ a year. Sesame later described the program as a beta that launched in November 2021. The subscription model added a recurring revenue stream alongside the core pay-per-visit business, and introduced the recurring billing that later drew customer complaints.

major2021-12-21

Competitor MDSave sues Sesame over patents, ads and alleged scraping

MDSave, a rival healthcare price marketplace, sued Sesame in federal court in Texas. Besides patent claims, it alleged false advertising (that Sesame's website statement about its relationships with providers was false) and that Sesame scraped listings from MDSave's public website. These were allegations, never findings.

minor2022-02-01

Sesame named to NYC Digital Health 100 second consecutive year

Sesame was named to the NYC Digital Health 100 list by New York City Health Business Leaders for the second consecutive year, recognizing it among the most innovative digital health startups in the New York region. The recognition followed the company's rapid growth from a two-city marketplace to a national platform serving hundreds of thousands of patients.

major2022-02-16

Sesame for Employers launches from $20/employee/month

Sesame rolled out Sesame for Employers, customizable health benefits for small and medium-sized businesses for as little as $20 per employee per month. Benefits could include same-day and unlimited telehealth appointments, access to Sesame's specialists, mental health services and digital prescriptions. Sesame claimed the employer product was 95% cheaper than the cost of insurance.

minor2022-04-12

Sesame partners with TeleDentists for dental-medical integration

Sesame and The TeleDentists announced a partnership to offer virtual dental consultations 24/7/365 nationwide on the Sesame platform, with triage to in-person specialists when needed. The initiative expanded Sesame's service range beyond medical care into dental, further diversifying the marketplace offering.

major2022-06-14

Sesame secures $27M Series B led by Google Ventures

Sesame closed a $27 million Series B round led by GV (Google Ventures), with new investors Virgin Group, TeleSoft Partners, and FMZ Ventures. Cathy Friedman, Executive Venture Partner at GV, was to join Sesame's board. The round brought total funding to $75 million and was earmarked to move the Sesame membership from beta to general availability; Sesame said members booked 33% more appointments than non-members.

minor2022-06-14

Sesame Plus reported at $10.99 a month before broad rollout

TechCrunch reported that the Sesame Plus membership, still in beta and due for broad rollout in 2022, cost $10.99 a month or $99 a year. It had launched in November 2021 at $7 a month.

minor2022-10-12

Sesame selected to power California's COVID-19 telehealth equity program

Sesame announced it had been selected to power California's Test to Treat Telehealth Equity Program. Uninsured, underinsured and underserved Californians who tested positive for COVID-19 and had symptoms could get a state-paid consultation with a Sesame provider, plus free drug therapy if clinically eligible.

major2022-11-07

Research study identifies third-party PHI leakage on Sesame

An academic study presented at ACM WPES 2022 found that Sesame Care, the Sesame service loaded on athenahealth-hosted provider sites, leaked Protected Health Information to third parties through tracking technologies. Lab test type and testing location went to Amplitude, while appointment dates, appointment topics and the health provider name went to Google Analytics, DoubleClick and Facebook Pixel. The study found PHI leaks on all four telehealth sites it examined, Sesame among them.

minor2022-11-15

Sesame @ Work launches for high-deductible health plans

Sesame unveiled Sesame @ Work, targeting employees enrolled in high-deductible health plans (HDHPs). Unlike Sesame for Employers, this product cost employers nothing — no flat fees and no per-member/per-month costs. Employees could apply Sesame expenditures toward their annual insurance deductible, and a loyalty program credited users for repeat visits.

minor2023-01-11

Texas court dismisses MDSave's patent claims against Sesame for improper venue

The Western District of Texas granted Sesame's motion to dismiss MDSave's patent claims for improper venue and dismissed some non-patent claims, but denied dismissal of the Lanham Act claims. The ruling was procedural and did not decide whether MDSave's allegations were true.

minor2023-06-11

Sesame @ Work announces first enterprise partners

Sesame announced Ameriplan, Tandem, and YouDecide as its first Sesame @ Work partners. The program let employers, benefits brokers, gig platforms and membership associations offer their members and workers access to the Sesame marketplace at no cost to the organization, with no flat fees or per-member/per-month charges.

major2023-07-20

FTC and HHS warn telehealth providers about tracking technologies

The FTC and HHS's Office for Civil Rights jointly sent letters to approximately 130 hospital systems and telehealth providers warning about privacy and security risks from online tracking technologies like Meta Pixel and Google Analytics. The agencies reiterated that HIPAA rules apply to data collected through tracking technologies. The letters did not name Sesame; a 2022 academic study had found tracker-based PHI leaks on Sesame's service.

minor2023-08-16

MDSave's refiled case against Sesame dismissed with prejudice

MDSave refiled patent claims against Sesame in the District of Delaware on June 12, 2023. On August 16, 2023 the parties stipulated to dismiss all claims against Sesame with prejudice, each bearing its own fees and costs; the terms behind the dismissal were not made public.

critical2023-09-25

Costco partnership launches with $29 virtual primary care

Sesame and Costco announced a partnership offering Costco members discounted healthcare services: $29 virtual primary care visits, $79 mental health therapy, and $72 health checkups including lab work. The deal gave Sesame access to Costco's 70+ million member base and represented a significant customer acquisition channel. Members also received 10% off all other Sesame services.

major2024-04-02

Costco weight loss program expansion with GLP-1 access

Sesame expanded its Costco partnership to include specialized weight loss care at $179 for Costco members. The program included three months of clinical consultation with a patient-selected clinician, video consultations, inter-appointment messaging, a nutritional guide, and when clinically appropriate, prescriptions for weight loss medications including Ozempic and Wegovy.

major2024-08-21

Success by Sesame launches compounded semaglutide at cost

Sesame unveiled Success by Sesame, a direct-to-consumer weight loss program offering compounded semaglutide at $249/month with no retail markup. The company selected a 503B compounding pharmacy and sold the medication at Sesame's cost. Eligible patients, particularly those with insurance, could instead be prescribed name-brand GLP-1 medications, with the program priced at $89/month excluding the branded drug.

minor2024-10-16

Sesame becomes first to offer compounded semaglutide in all 50 states

Sesame announced it had begun offering compounded semaglutide in Alabama, California, Louisiana, and Mississippi. Its release said this made Sesame the first major direct-to-consumer weight loss company to offer the medication to eligible patients in all 50 states, a claim not independently confirmed.

major2024-11-24

Sesame CMO Marty Makary nominated as FDA commissioner

President-elect Trump picked Dr. Martin Makary, Sesame's Chief Medical Officer, to lead the FDA. STAT reported his executive role at Sesame, whose providers prescribe compounded weight-loss drugs, raising conflict-of-interest questions because FDA decisions on drug shortage lists and compounding rules affect that business. Roll Call reported on March 5, 2025, citing Makary's ethics disclosure, that he resigned from Sesame in December 2024, before his Senate confirmation hearing.

minor2025-01-13

Sesame offers free telehealth for LA wildfire victims

Sesame made more no-cost virtual healthcare appointments available to Los Angeles residents affected or displaced by the January 2025 wildfires, through providers on its marketplace, including primary care and prescription refill appointments (excluding controlled substances) and mental health medication management. Patients did not need health insurance.

critical2025-02-21

FDA declares semaglutide shortage over, threatening compounding model

The FDA officially declared the semaglutide (Ozempic and Wegovy) shortage resolved. Because compounded versions of drugs are generally only permitted when branded versions are in shortage, the decision threatened the compounded GLP-1 business of telehealth companies such as Hims & Hers. Sesame, whose weight loss program offered both branded and compounded semaglutide, said through co-founder and president Michael Botta that the declaration would not affect its business.

minor2025-03-24

Sesame integrates Zepbound through LillyDirect partnership

Sesame announced a technical integration with Gifthealth, the LillyDirect Self Pay Pharmacy Solutions dispensing provider, to streamline access to Eli Lilly's Zepbound obesity medication. Eligible Sesame patients without insurance coverage could receive Zepbound vials at $349 (2.5mg) or $499 (5mg, 7.5mg and 10mg) per month. The move diversified Sesame's weight loss offerings beyond compounded drugs.

minor2025-05-19

Sesame partners with Health-E Commerce for FSA/HSA store access

Health-E Commerce launched a collaboration making Sesame's mental health and dermatology services available on FSA Store and HSA Store. Dermatology services started at $59/month and mental health services at $79/month with unlimited messaging and video visits. The partnership allowed consumers to pay for Sesame services using pre-tax health savings accounts.

major2025-09-09

FDA warns telehealth firms over compounded GLP-1 advertising

The FDA and HHS announced a broad initiative to address misleading direct-to-consumer pharmaceutical advertisements, sending thousands of warning letters and approximately 100 cease-and-desist letters to companies with deceptive ads. Several GLP-1 telehealth providers were targeted. The regulatory action increased scrutiny on telehealth companies offering compounded weight loss drugs, including Sesame's market segment.

major2026-01-22

Sesame launches Wegovy pill through Novo Nordisk collaboration

Sesame partnered with Novo Nordisk as a NovoCare Recognized Care Provider to offer the newly FDA-approved Wegovy pill, the first oral GLP-1 for weight management. The comprehensive weight loss program started at $99/month with medication costs from $25/month for commercially insured patients or $149/month for self-pay. This shifted Sesame's weight loss business toward branded FDA-approved drugs.

major2026-03-09

Sesame launches fertility program with Costco and IVI RMA

Sesame, Costco and IVI RMA North America announced a fertility partnership: for $99 a month with a Costco membership, or $119 without, patients meet virtually with a doctor of their choice on Sesame for a fertility intake and diagnostic workup, with referral to IVI RMA clinics for specialized care.

minor2026-05-13

Former Sesame CMO Marty Makary's FDA tenure ends

The FDA's leadership page lists Marty Makary, Sesame's former Chief Medical Officer, as Commissioner of Food and Drugs from March 25, 2025, when the Senate confirmed him, through May 13, 2026. His tenure covered the period when the FDA's compounding and shortage decisions bore on Sesame's weight-loss business.

minor2026-06-04

Sesame added to LillyDirect; reports one million patients served

Sesame announced it had been added to Eli Lilly's LillyDirect platform as an option for obesity and diabetes care, with visits from $34 and prices shown before booking. The company said it had served more than one million patients across all 50 states, with a 95% patient satisfaction rate (company-reported) and a 4.5 Trustpilot rating.

Evidence (42 citations)

D10: Regulatory & Legal Posture

Scoring Log (7 entries)
regrade2026-10-26RESCORED

20->21. D6 3->4 (event: Oct 2026 terms require membership cancellation by email or phone 48h before renewal with no proration; BBB shows 117 complaints in 3 years incl. 2026 enrollment-after-one-visit complaints). All other dimensions confirmed. Since Feb 2026: fertility program with Costco/IVI RMA (Mar 2026, $99-119/mo), Makary's FDA tenure ended (May 2026), LillyDirect listing and 1M+ patients claim (Jun 2026), Everyday Rx $29-59/mo subscription, terms/privacy policy updated Oct 2026; no enforcement, funding, layoffs or litigation. Eras: 'Direct-Pay Founding' re-dated 2018-10-01->2018-10-18 (founding); 'COVID Telehealth Pivot' re-dated 2020-09-01->2020-03-15 (virtual pivot); 'Platform Expansion' re-dated 2022-01-01->2021-11-18 (Sesame Plus launch); 'Costco-Era Growth' re-dated 2026-02-19->2023-09-25 (Costco partnership) and split at 2024-08-21 (Success by Sesame) into 'Costco-Era Growth' + new 'GLP-1 Subscription Push'. Historical gaps filled: 2019 Form D, 2020 10% fee disclosure, MDSave suit (2021) and its 2023 outcomes, Sesame Plus $10.99 (2022), California COVID equity program (2022). Skipped: Fifth Circuit semaglutide shortage ruling (does not name Sesame), temporary Foundayo promo, terms/privacy dating events. Category 'Telehealth' fine.

restore-check2026-10-26RESTORED

Checked all 7 candidates: 1 restored, 0 partly restored, 3 confirmed removed, 3 already present. RESTORED timeline:update:21: Roll Call (2025-03-05), citing Makary's ethics disclosure, says he resigned from Sesame in December 2024, before his confirmation hearing; PharmaVoice (2025-03-07) corroborates resignation. Added Roll Call evidence (RESTORED supporting citation) and corrected only the D9 narrative's departure timing. CONFIRMED REMOVED timeline:update:0: $4.96M seed figure absent from readable CB Insights profile/financials; three searches (exact 4.96 with Sesame funding; 4.96 million with Goldhill; EasyCare Health 2018/2019 seed origin) found no usable support. CB Insights archive and 2018 Form D fetch failures were not treated as negative evidence. Readable 2019 Form D instead reports $23,648,688 sold. CONFIRMED REMOVED timeline:update:6: two-day delivery absent from both live and September 2021 Wayback MobiHealthNews article; three shipping searches and date-drift checks found Innerbody's 3-5 business days and Digital Health Times' September 2021 four-business-day account, not the dropped claim. CONFIRMED REMOVED timeline:update:19: original release's readable Wayback copy names no 14 options or Wegovy/Zepbound; three searches, including exact 14/medications wording and later-date checks, yielded only an unqualified ClearMetabolic comparison page for the 14 figure, which was read but not accepted as restoring evidence. Healthline also did not support it. Generic branded GLP-1 access remains in the current item. ALREADY PRESENT evidence:update:7: funding/investor coverage remains in CB Insights evidence index 6; its readable financials show $78.05M over four rounds and 14 investors. Original Crunchbase URL now readable via September 29, 2024 Wayback and positively identifies this healthcare Sesame, with $75M and the named founders; no lost factual claim or duplicate card to restore. ALREADY PRESENT evidence:update:18: provider no-show reports remain in D1 prose and existing BBB evidence; an AOL July 2, 2024 first-person report independently describes a no-show and refund. Live and archived App Store pages do not support the original no-show attribution; the corrected App Store card is retained. Three searches completed for this candidate. ALREADY PRESENT milestones:update:0: original founding date and label are unchanged; audit only added the SEC URL. Every supporting page was read this session; 15 web searches total, never more than three per candidate. No removals or score changes.

fact-audit2026-10-25FABRICATION FOUND

Checked 68 items (28 timeline, 35 evidence, 3 milestones, 2 alternatives) + prose. 20 verified, 34 corrected (18 date-only), 11 re-sourced, 3 removed (1 wrong entity, 1 contradicted, 1 unsupported). Invented: (a) Heap Analytics PHI leaks attributed to Sesame in timeline/narrative/era summary; the WPES 2022 paper attributes them to PlushCare; (b) LeafSnap evidence titled 'Hidden Charges for Additional Tests' while the page says Sesame shows upfront test prices. Also fixed: $4.96M seed (Form D shows $3.4M), unsupported $10.1M 2023 round, Sesame Plus launch price ($7 not $10.99), stale Teladoc revenue, BBB A to A+, Trustpilot review count, Makary resignation claim, Zepbound dose range, refund windows.

deep-enrichment-reset2026-03-22

Stripped for Phase 2 re-enrichment

Deep Enrichment2026-03-22
Alternatives Review2026-02-21GOOD
Initial Scoring2026-02-19